Age-stratified analysis showed significant signals in the younger patients group for endocardial disorders with ponatinib (BCR-ABL) and pericarditis with brigatinib (ALK), with no reports in the older patients group (Figures 5A, B). This evidence concerns the gene BCR and pericarditis.